These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25934709)

  • 1. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
    Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
    Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
    Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
    Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
    Deng L; Li G; Li R; Liu Q; He Q; Zhang J
    Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
    Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Li ZY; Zhang RG; Zhu F; Wu G
    Int J Cancer; 2019 May; 144(9):2227-2238. PubMed ID: 30374974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
    Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L
    Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
    Miyamoto C; Maehata Y; Ozawa S; Ikoma T; Kubota E; Izukuri K; Kato Y; Hata R; Lee MC
    J Pharmacol Sci; 2012; 120(3):241-9. PubMed ID: 23099322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fasudil inhibits prostate cancer-induced angiogenesis in vitro.
    Chen W; Mao K; Hua-Huy T; Bei Y; Liu Z; Dinh-Xuan AT
    Oncol Rep; 2014 Dec; 32(6):2795-802. PubMed ID: 25333508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor.
    Hata Y; Miura M; Nakao S; Kawahara S; Kita T; Ishibashi T
    Jpn J Ophthalmol; 2008; 52(1):16-23. PubMed ID: 18369695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
    Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H
    Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures.
    O E; Ahn HY; Kim HK; You JC; Shin JC; Joe YA
    Int J Mol Med; 2011 Sep; 28(3):357-63. PubMed ID: 21567077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
    Chen XY; Dun JN; Miao QF; Zhang YJ
    Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
    Yin L; Morishige K; Takahashi T; Hashimoto K; Ogata S; Tsutsumi S; Takata K; Ohta T; Kawagoe J; Takahashi K; Kurachi H
    Mol Cancer Ther; 2007 May; 6(5):1517-25. PubMed ID: 17513600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fasudil protects cultured N1E-115 cells against lysophosphatidic acid-induced neurite retraction through inhibition of Rho-kinase.
    Satoh S; Kawasaki K; Hitomi A; Ikegaki I; Asano T
    Brain Res Bull; 2011 Feb; 84(2):174-7. PubMed ID: 21126559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
    Nakabayashi H; Shimizu K
    Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
    Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
    Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway.
    Li Y; Wu Y; Wang Z; Zhang XH; Wu WK
    Med Sci Monit; 2010 Apr; 16(4):BR112-118. PubMed ID: 20357711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.
    Li H; Peng W; Jian W; Li Y; Li Q; Li W; Xu Y
    Cardiovasc Diabetol; 2012 Jun; 11():65. PubMed ID: 22694757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer.
    Yang X; Di J; Zhang Y; Zhang S; Lu J; Liu J; Shi W
    Biomed Pharmacother; 2012 Apr; 66(3):221-7. PubMed ID: 22425182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
    Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
    Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells.
    Yang X; Liu Y; Zong Z; Tian D
    Biomed Pharmacother; 2010 Jan; 64(1):58-62. PubMed ID: 19879105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.